Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
3 search results for:

Thomas Stinchcombe 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 09-10-2019 | Non-small-cell lung cancer | Editorial | Article

    Current therapies for advanced NSCLC: The role of maintenance therapy in an immunotherapy world

    Thomas Stinchcombe (Duke Cancer Institute, USA) examines the development of maintenance regimens and where they fit as immunotherapy continues to change treatment paradigms for NSCLC.

    Author:
    Thomas Stinchcombe
  2. 30-08-2019 | Non-small-cell lung cancer | News | Article

    No survival benefit with erlotinib–bevacizumab in stage IV NSCLC

    Lead author Thomas Stinchcombe (Duke Cancer Institute, Durham, North Carolina, USA) and colleagues say that subsequent therapies are unlikely to have affected the OS results as these were similar across the groups, and a comparable proportion of patients in both arms received second-line osimertinib.

    Published in:
    JAMA Oncol 2019; doi:10.1001/jamaoncol.2019.1847
  3. 18-05-2017 | Non-small-cell lung cancer | News | Article

    Selumetinib adds no benefit to docetaxel in KRAS-mutant advanced NSCLC

    Commenting on the findings in an accompanying editorial , Jacob Kaufman (Duke University, Durham, North Carolina, USA) and Thomas Stinchcombe (Duke Cancer Institute, Durham, North Carolina, USA) say: “The oncology community will be left seeking an explanation for these nonsignificant trial results and wondering what next investigational path should be pursued in this population.”

    Published in:
    JAMA 2017; 317 : 1835–1837, 1844–1853
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.